Objective: We undertook a meta-analysis of randomised trials assessing the outcome of vascular brachytherapy (VBT) or DES for the treatment of coronary artery ISR. Methods and results: Studies utilising DES or VBT for ISR were identified by a systematic search. Data was pooled and combined overall effect measures were calculated for a random effect model in terms of deaths, myocardial infarctions, revascularisation, binary restenosis, mean late luminal loss and major adverse cardiac events (MACE). Fourteen eligible studies (3103 patients) were included. Neither therapy had any effect on mortality or myocardial infarction rate. VBT reduced the rate of revascularisation (RR 0.59, 95%CI 0.50-0. 
Introduction
Catheter based percutaneous interventions have become the primary invasive treatment for coronary artery disease [1] . A significant problem associated with this therapy has been the high recurrence rate. The introduction of drug eluting stents (DES) has dramatically reduced the incidence of in-stent restenosis (ISR) following percutaneous coronary interventions [2] . However, ISR continues to be a problem in the treatment of some patients such as those with small vessels or diabetes mellitus where rates over 10% have been reported [3, 4] . Historically the treatment of ISR has been disappointing with techniques such as cutting balloons, atherectomy devices and bare metal stents failing to improve the outcome over angioplasty alone [5] [6] [7] . Vascular brachytherapy (VBT) was introduced to reduce recurrence following coronary interventions and present guidelines advocate its use for the treatment of ISR with level I evidence [8] . The restricted availability, need for specific licensing, and more cumbersome treatment delivery have all limited the use of VBT to specialist centres [9] . Given the success of DES in primary coronary lesions their use has recently been advocated for ISR [10] . We carried out a meta-analysis to examine the outcome of VBT and DES in the treatment of coronary artery ISR.
Methods

Search strategy
This meta-analysis was carried out in accordance with the standard protocol recommended by the Quality of Reporting of Meta-analyses group [11] . An extensive literature search for randomised controlled trials addressing the management of ISR was conducted from August 10, 2005 to April 26, 2006 (see Supplemental data available on-line). In all 17 trials were considered potentially appropriate for inclusion in this meta-analysis.
Study selection
Eligible studies were randomised controlled trials assessing the use of VBT or DES in patients with native coronary artery ISR. Mixed studies in which a subset of the participants only had ISR (others having primary lesions or non-stent restenosis) were allowable although sensitivity analyses were planned to assess the effect of including such studies. The proportion of patients with ISR in these mixed studies is illustrated in Table 1 . At least one treatment group needed to use VBT or DES. Trials were also considered if they referred either to intravascular or intracoronary instead of 'vascular', and radiotherapy or radiation instead of 'brachytherapy' when describing the VBT treatment. We required that outcome should have been assessed for a minimum of 6 months following treatment of ISR by clinical and angiographic measures. VBT -Vascular brachytherapy group, DES -Drug-eluting stent group, C -Control group, () denotes standard deviation values (unless study is marked with a ⁎ , indicating interquantile range), DM -diabetes mellitus, MVD -multivessel disease, TLL -target lesion length, MLD -minimum luminal diameter, S -sirolimus stent group, P -paclitaxel stent group, n/r -not reported.
Data extraction and validity assessment
Two authors (LO and HH) independently extracted the data from the identified studies. Any discrepancies were resolved with discussion until agreement was met. In the event of missing or difficult to interpret data, the chief investigator of the study concerned was contacted directly for further information. The quality of the studies was assessed independently by two authors (JG and PB). These assessors were blinded to names, affiliations and addresses of the investigators as well as to the journals in which the trials were published. Quality assessment was based on three scales: 1) the 17 checklist items required in the methods and results of randomised controlled trials according to the CONSORT statement; 2) a scale of six criteria devised by our group in order to assess hypothesis setting, outcome assessment, randomisation, blinding, reporting of patient numbers and analysis (score ranging from 0 to 8); and 3) the previously validated scale by Jadad et al. (score ranging from 0 to 5) [12, 13] . Agreement between the two assessors was judged using the concordance correlation coefficient [14] . For each scale the scores from the two assessors was added and ranked to determine the trials of high and low quality.
Study characteristics and definitions
The study design, patient characteristics, target lesion characteristics, procedural details, outcomes measures, and follow-up periods were reviewed to assess clinical heterogeneity. The components of the study design that were noted included the blinding of the studies as well as the number of centres involved in recruiting patients. The trials were noted to be unblinded, single-blinded or double-blinded based on whether treatment allocation was concealed from the patient, treating physician and/ or outcome assessor. Characteristics of the study participants that were noted included age, gender, the presence of diabetes mellitus and multi-vessel disease. Lesion characteristics recorded included the classification of stenosis (primary, non-stent restenosis (NSR), and ISR), lesion length and the initial minimal lumen diameter (MLD). The trial intervention details recorded included the application and source (beta or gamma radiation) of VBT, the type of DES (sirolimus or paclitaxel stents), and the frequency of balloon angioplasty, bare-metal stent placement, atherectomy (direct or rotational) or excimer laser angioplasty.
Outcome assessment
The outcome measures considered included the angiographic endpoints of binary restenosis and late lumen loss, as well as the clinical outcome of major adverse cardiac events (MACE), a composite of the number of deaths, myocardial infarctions (MI), and either target vessel revascularisation (TVR) or target lesion revascularisation (TLR), as defined by each study. A breakdown of MACE into the individual components also provided additional outcome measures.
While all studies reported outcome at the same period after intervention for treatment and control patients the exact time points varied from study to study. Therefore clinical measures were recorded as short-term (in-hospital or 30-day events), intermediate (6-24 months) , and long-term followup (3 years or more). Short-term results were preferentially taken from the 30-day event rates, intermediate outcomes were preferentially taken from the 12-month assessment and long-term results were preferentially taken from the 3-year findings. For definitions of outcome measures see Supplemental data (available on-line).
Quantitative data synthesis
For categorical outcome characteristics relative risks were chosen as treatment effect measures. For late loss standardised differences in means were calculated. Combined overall effect measures were calculated for a random effect model and are presented with 95% confidence intervals (95%CI). Statistical heterogeneity was assessed using the chi-square distributed Q-statistic. Sensitivity analyses were carried out differentiating between (1) studies in which participants all had ISR and those with mixed patients including some with primary lesions or NSR in addition to ISR; (2) trials using gamma and those using beta radiation; (3) studies with a follow-up time of 1 year or more and those with a shorter observation period; (4) trials utilising DES and those using VBT; and (5) studies that were judged to be of lower quality against all other studies. Publication bias was assessed graphically using funnel plots and statistically using the classic fail-safe N. Statistical analysis was conducted using the software program Comprehensive Meta-Analysis, Version 2 (Englewood, NJ 07631, USA).
Results
Study characteristics
We identified 17 randomised controlled trials assessing the efficacy of VBT for ISR of which 14 met our inclusion criteria (3103 participants, Supplemental Fig. 1 available online) . Three additional trials (ARREST, ARTISTIC, BRITE) were unable to be included as there was incomplete reporting of the results [36, 37] . The chief investigators for each of these trials were contacted for further information but were unable to provide any assistance. Two trials (TAXUS V ISR, SISR) evaluated the use of VBT compared to DES in the treatment of ISR [34, 35] . One study (ISAR-DESIRE) addressed the use of DES compared to a control group and eleven trials addressed the use of VBT compared to control groups [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . The design of the trials is shown in Supplemental Table 1 (available on-line) and the patient and lesion characteristics in Table 1 .
Around one-third of patients treated had diabetes mellitus, mean TLL and MLD were over 15 mm and less than 9 mm respectively in the majority of studies (Table 1) . VBT followed balloon angioplasty plus selective placement of bare-metal stents (BMS) and/or atherectomy in the majority of studies with comparable interventional treatment being used in the control patients except in two studies where VBT was compared with DES [34, 35] . Agreement between the assessors of study quality was low for Jadad ' . Both independent and blinded assessors of the studies agreed on judging two of the 14 studies of lower quality [18, 23] . VBT -Vascular brachytherapy group, DES -Drug-eluting stent group, Control -Control group (PTCA), MACE-major adverse cardiac event, MImyocardial infarction defined as either Q wave or non-Q wave infarction, TLR -target lesion revascularisation, TVR -target vessel revascularisation, Short-term: in-hospital complications or 30-day MACE, Intermediate: 6-24mth MACE, Long-term: 36mth MACE, n/r -not reported.
Trial outcomes
The clinical outcomes in the trials are reported in Table 2 . The angiographic follow-up and outcome of the trials are shown in Supplemental Table 2 (available online).
Outcome of brachytherapy compared to other treatment options
Thirteen of the studies compared VBT with another treatment, either PTCA plus selective BMS (n = 11) or DES (n = 2). By comparison with all other treatments VBT c One study recorded no TLR in both intervention and control groups (Schühlen et al) and one study did not record TLR (SPARE). d Heterogeneity persisted after exclusion of TAXUS and SISR mainly caused by the large effects of the two studies that were considered of less quality (Schühlen et al and PREVENT). However, even after exclusion of those studies heterogeneity was significant (Q = 17.5; p = 0.025 including 9 studies).
e Both TAXUS V ISR and SISR had no long-term follow-up. Only five studies (3 pure ISR studies; see Table 1 ) had long-term follow-up.
reduced the odds of MACE, TVR, TLR, restenosis and late loss at intermediate follow-up and MACE at long-term follow-up (Table 3 , Supplemental Fig. 2 available on-line). Heterogeneity was significant for TVR, TLR, MACE after 1 year, restenosis and late loss (p b 0.001, respectively). Exclusion of the two studies TAXUS and SISR which compared DES with VBT reduced heterogeneity to insignificance in all analyses except for late loss (Table 3) . Heterogeneity for the late loss results persisted even after further exclusion of the two studies that were considered of less quality (Schuhlen et al. and PREVENT) which showed comparably large effects for late loss. A sensitivity analysis was conducted removing the two studies considered of less quality, which resulted in findings almost identical to the initial results. Differences between results generated by fixed and random effect models were minimal. The studies were stratified into those studying "pure" in-stent restenosis lesions (n = 9) and those including "mixed" lesions (n = 4).
Results for the two groups were very similar except that VBT had no effect on TVR or TLR in the pure ISR studies. When the two DES studies (TAXUS and SISR) were excluded from the analyses VBT was superior in terms of MACE, TVR, TLR, restenosis and late loss in the "pure" in-stent restenosis group (Table 3) . Further sensitivity analyses are available in the Supplemental data (available on-line).
Outcome of DES compared to other treatment options
Combined numerical results of all studies with DES as one treatment arm (n = 3) showed significant reductions of TVR, MACE assessed after 1 year follow-up, and restenosis for the intervention compared with control group (p b 0.001, respectively) (Table 4) . Similar results were found when analysis was restricted to the two studies that compared DES against VBT (Table 4 , Supplemental Figs. 3-5 available on-line). In addition, the combined results of the two DES studies that compared against VBT also showed a significant reduction in TLR. For these analyses heterogeneity was not significant. Further sub-group analyses were not conducted because of the small sample size.
Discussion
Vascular brachytherapy (VBT) has been the principal scientifically investigated local therapy for coronary artery ISR. In this meta-analysis we compared the outcome of VBT and other therapies for ISR. In 11 studies the addition of VBT to standard treatment of ISR was assessed. While in 2 studies VBT following balloon angioplasty plus selective BMS (in approximately 16%) was compared with DES placement. A total of three studies were identified comparing DES with other treatments for ISR [33] [34] [35] . Two of these studies compared DES with VBT (mentioned above) and one with balloon angioplasty plus selective BMS placement (mean 4%).
Our overall findings demonstrate that VBT improves intermediate term outcome in terms of binary restenosis, late lumen loss, need for revascularisation and MACE in the treatment of ISR by comparison to balloon angioplasty and selective BMS placement (Tables 2-4 ). This finding is only apparent in the 11 studies comparing VBT with similar treatment in the control patients and is unaffected by radiation source, removal of lower quality studies and those with shorter follow-up. Analysis of the three studies comparing DES with other treatments for ISR demonstrated reduced need for revascularisation, MACE and binary restenosis in patients receiving DES. This finding included benefit of DES over VBT in all these three outcome measures. Although it should be noted that DES have not been compared with VBT following obligate placement of BMS i.e. the difference in outcome identified may result from an effect of the stent in addition to the eluted drug. Neither VBT nor DES was shown to reduce mortality, myocardial infarction or improve short-term outcome. In addition DES was not shown to reduce late lumen loss, which is believed to be the most robust measure of restenosis [38] .
The benefit of coronary interventions which do not reduce the clinical end-points of death and myocardial infarction have been questioned since restenosis has not been linked to these more significant events in some studies [39] . Coronary intervention studies have been criticised for focusing too much on restenosis which when identified by the protocol-driven angiogram defines the need for revascularisation. In this regard most investigators left decisions regarding re-intervention to the local treating physician. However, TAXUS V ISR which compared paclitaxel-eluting stents and VBT attempted to isolate ischaemia driven revascularisation [35] . This was defined as at least 50% binary restenosis associated with electrocardiographic changes at rest or a positive functional study in the distribution of the vessel or at least 70% stenosis associated with recurrent symptoms. The investigators reported a small but significant reduction in the rate of ischaemia driven revascularisation in favour of the DES treated patients (Supplemental Fig. 3 available on-line) .
A number of meta-analyses have demonstrated the benefit of DES over BMS in terms or restenosis and MACE but not mortality in the treatment of primary coronary lesions at 12 months [2, 40] . In keeping with the findings from this study Dibra and colleagues have recently reported improved outcome of DES compared to other therapies for ISR in a meta-analysis of four studies [41] . Outcome was only superior for DES in terms of target lesion revascularisation and restenosis not mortality, as in the present report. It should be noted that long-term assessment is limited in most of the studies assessed in the present and other meta-analyses. In the present meta-analysis only 5 studies had follow-up over 2 years. Analysis of these studies demonstrated superiority of VBT over standard treatments in terms of reduced need for revascularisation and MACE. However, all the DES studies had 12 months or less follow-up. This is particularly important to note given the increasing concern regarding late thrombosis following placement of DES [42] .
In conclusion the results of this meta-analysis confirm the efficacy of VBT over BMS for ISR. The results of DES for ISR appear to be at least as good as VBT within the first 12 months. However, larger studies with longer follow-up are required to address whether the favourable results of DES are maintained.
